Plasma Brain Natriuretic Peptide after Isolated On-Pump Coronary Artery Bypass Grafting: Prediction of Postoperative Adverse Outcomes
DOI:
https://doi.org/10.1532/HSF98.20071185Abstract
Background. The heart is an endocrine organ that synthesizes 2 different natriuretic peptides: atrial natriuretic peptide and brain natriuretic peptide (BNP). We assessed the relationship between preoperative BNP levels and postoperative complications and outcomes in patients who undergo isolated coronary artery bypass grafting (CABG).
Method and Results. The study consisted of 85 patients undergoing first-time elective CABG. Preoperative BNP levels were significantly correlated with the preoperative ejection fraction (P = .004), the number of vessels grafted (P = .016), cross-clamp time (P = .041), and perfusion time (P = .032). Preoperative BNP levels were higher in patients who developed postoperative new-onset atrial fibrillation (AF) (median BNP, 197 pg/mL versus 65 pg/mL; P = .006), in patients requiring inotropic support (189 pg/mL versus 65 pg/mL; P = .004), and in patients who required an intra-aortic balloon pump (IABP) (325 pg/mL versus 68 pg/mL; P= .021). Analysis of receiver operating characteristic curves demonstrated the preoperative BNP level to be a predictor of new-onset AF, a need for inotropic support, and a requirement for an IABP (areas under the curve, 0.70, 0.70, and 0.79, respectively). BNP cutoff values of 100 pg/mL for AF, 185 pg/mL for inotropic support, and 235 pg/mL for requiring an IABP predicted these postoperative adverse outcomes with 65%, 73%, and 84% accuracy, respectively.
Conclusion. This study suggests that a higher baseline plasma BNP concentration is associated with postoperative new-onset AF, a need for inotropic support, and an IABP requirement in patients who undergo first-time isolated CABG.
References
Bettencourt P, Ferreira S, Azevedo A, Ferreira A. 2002. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med 113:215-9.nCheng V, Kazanagra R, Garcia A, et al. 2001. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37:386-91.nDao Q, Krishnaswamy P, Kazanegra R, et al. 2001. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37:379-85.nDupuis JY, Wang F, Nathan H, Lam M, Grimes S, Bourke M. 2001. The cardiac anesthesia risk evaluation score: a clinically useful predictor of mortality and morbidity after cardiac surgery. Anesthesiology 94:194-204.nFrancis GS, Benedict C, Johnstone DE, et al. 1990. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82:1724-9.nGottlieb SS, Kukin ML, Ahern D, Packer M. 1989. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 13:1534-9.nHiggins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM, Paranandi L. 1992. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients: a clinical severity score. JAMA 267:2344-8.nHutfless R, Kazanegra R, Madani M, et al. 2004. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol 43:1873-9.nKrishnaswamy P, Lubien E, Clopton P, et al. 2001. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 111:274-9.nMaeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. 1998. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135:825-32.nMaisel A. 2001. B-type natriuretic peptide levels: diagnostic and therapeutic potential. Cardiovasc Toxicol 1:159-64.nMaisel AS, Krishnaswamy P, Nowak RM, et al., for the Breathing Not Properly Multinational Study Investigators. 2002. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-7.nMartinez-Alario J, Tuesta ID, Plasencia E, Santana M, Mora ML. 1999. Mortality prediction in cardiac surgery patients: comparative performance of Parsonnet and general severity systems. Circulation 99:2378-82.nMcCullough PA, Nowak RM, McCord J, et al. 2002. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106:416-22.nMorita E, Yasue H, Yoshimura M, et al. 1993. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82-91.nNozaki N, Yamaguchi S, Shirakabe M, Nakamura H, Tomoike H. 1997. Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. Jpn Circ J 61:657-64.nOmland T, Persson A, Ng L, et al. 2002. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106:2913-8.nParsonnet V, Dean D, Bernstein AD. 1989. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation 79:13-12.nPons JM, Espinas JA, Borras JM, Moreno V, Martin I, Granados A. 1998. Cardiac surgical mortality: comparison among different additive risk-scoring models in a multicenter sample. Arch Surg 133:1053-7.nProvenchere S, Berroeta C, Reynaud C, et al. 2006. Plasma brain natriuretic peptide and cardiac troponin I concentrations after adult cardiac surgery: association with postoperative cardiac dysfunction and 1-year mortality. Crit Care Med 34:995-1000.nRichards AM, Nicholls MG, Espiner EA, et al. 2003. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107:2786-92.nSaribulbul O, Alat I, Coskun S, et al. 2003. The role of brain natriuretic peptide in the prediction of cardiac performance in coronary artery bypass grafting. Tex Heart Inst J 30:298-304.nShirasawa B, Hamano K, Kawamura T, et al. 2000. Does the serum brain natriuretic peptide (BNP) level after open heart surgery reflect myocardial protection? [in Japanese]. Kyobu Geka 53:123-6.nTroughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. 2000. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126-30.nTu JV, Jaglal SB, Naylor CD. 1995. Multicenter validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery. Steering Committee of the Provincial Adult Cardiac Care Network of Ontario. Circulation 91:677-84.nTuman KJ, McCarthy RJ, March RJ, Najafi H, Lvankovich AD. 1992. Morbidity and duration of ICU stay after cardiac surgery: a model for preoperative risk assessment. Chest 102:36-44.nWazni OM, Martin DO, Marrouche NF, et al. 2004. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 110:124-7.nWeightman WM, Gibbs NM, Sheminant MR, Thackray NM, Newman MA. 1997. Risk prediction in coronary artery surgery: a comparison of four risk scores. Med J Aust 166:408-11.nWendelboe Nielsen O, Kirk V, Bay M, Boesgaard S, Nielsen H. 2004. Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study (CHHF). Eur J Heart Fail 6:275-9.nYasue H, Yoshimura M, Sumida H, et al. 1994. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195-203.n
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
